Introduction: Women with polycystic ovary syndrome (PCOS) have higher prevalence of metabolic syndrome (MS) than healthy, age and BMI matched women. The aim of this study was to determine if novel abdominal adiposity index lipid accumulation product (LAP), could predict MS in women with PCOS.
Methods: PCOS was diagnosed using ESHRE/ASRM criteria. We evaluated 159 PCOS women (PCOS group: 24.9±6.2 kg/m2; 25.8±5.4 years) and 56 healthy women (control group: 22.9±5.8 kg/m2; 27.6±5.3 years). MS was diagnosed according to JIS criteria (waist circumference cut off 80 cm) in 39/159 (25%) PCOS women, while no woman in controls group had MS. PCOS group was divided in subgroups: PCOS with MS (31.9±5.4 kg/m2; 27.9±7.1 years) and PCOS without MS (22.8±4.6 kg/m2; 25.0±4.6 years). In all subjects blood pressure (BP) and waist circumference (WC) were determined. Blood samples were collected in follicular phase of menstrual cycle for determination of basal glucose, insulin, HDL-cholesterol, triglycerides, testosterone, SHBG and homeostatic model (HOMA) index. LAP was calculated using formula ((WC-58)×triglycerides). All statistical analyses were adjusted for age and body mass index.
Results: PCOS had significantly higher LAP than controls (37.3±43.5 vs 18.5±17.1, P<0.001). PCOS without MS had significantly lower LAP than PCOS with MS (20.6±17.5 vs 90.6±57.3, P<0.001) and significantly higher LAP than controls (P=0.016). JIS criteria for MS, testosterone, SHBG and LAP entered binary logistic regression analysis which showed that independent predictors for MS in PCOS group were: LAP (P=0.002), systolic BP (P=0.003) and HDL-cholesterol (P=0.004). In PCOS, LAP significantly correlated with HOMA (P=0.42, P<0.001).
Conclusion: LAP is useful surrogate marker for the assessment of metabolic syndrome in women with PCOS.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
05 - 09 May 2012
European Society of Endocrinology